Investment in Britain’s vital life sciences sector is under threat due to a deteriorating commercial environment. Senior executives from major pharmaceutical companies, including Johnson & Johnson, are voicing concerns that
All posts tagged in Life Sciences2- Page
22Articles
The recent decision by pharmaceutical giant AstraZeneca to abandon its £450 million investment plan in Liverpool has sparked serious concerns about Britain’s ability to attract and retain major corporate investments.
British pharmaceutical giant AstraZeneca has abandoned its £450 million expansion plans for its vaccine manufacturing facility in Speke, Liverpool, delivering a significant blow to the UK’s life sciences sector. The
A critical £450 million investment by pharmaceutical giant AstraZeneca in a new vaccines facility in Speke, Liverpool, has encountered significant delays due to prolonged government deliberations on support measures. The
Liverpool’s burgeoning life sciences sector is positioning itself as one of Europe’s premier biotech clusters, with projections indicating up to £800 million in investment over the next decade. The region’s
The fate of AstraZeneca’s planned £450 million investment in a vaccine manufacturing facility in northwest England hangs in the balance as the Treasury, under the leadership of Chancellor Rachel Reeves,
- 1
- 2
